Reply to "A call for reporting of tumor‐specific outcomes in studies of DPYD genotyping".

Autor:	El Rouby, Nihal, Allen, Josiah D., Muldoon, Megan, Beck, Mollie, Hesse, Kristina, Sebree, Nichlas, Yoder, Robin, Ritter, Stacey, Alqahtani, Zuhair, Grund, Jaime, Holbrook, Brooke Philips
Předmět:	METASTATIC breast cancer GASTROINTESTINAL cancer BREAST cancer CANCER prognosis RESEARCH personnel
Zdroj:	CTS: Clinical & Translational Science; Aug2024, Vol. 17 Issue 8, p1-2, 2p
Abstrakt:	This document is a reply to a letter to the editor regarding a publication titled "Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center." The authors of the publication acknowledge that due to a small sample size, they were unable to report outcomes by cancer type. They highlight that most research on DPYD outcomes focuses on gastrointestinal cancers, where the use of fluoropyrimidines is more common. The authors advocate for routine DPYD testing before administering fluoropyrimidines and suggest that large collaborative datasets analyzing outcomes by cancer type are needed to further assess tumor-specific outcomes. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.